Dupixent (dupilumab) Recommended for EU Approval by the CHMP

31.05.2024 - Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved lung function If approved, ...

Related Keywords

China , Paris , France General , France , Massachusetts , United States , Georged Yancopoulos , Regeneron Velocimmune , Regeneron Velocimmunetechnology , Regeneron Genetics Center , Drug Administration , Euronext , Regeneron Pharmaceuticals Inc , European Commission Of Dupixent , European Commission , European Union , Nasdaq , Exchange Commission , Dupilumab Development Program , Clinical Research Program , Us Department Of Justice , Linkedin , European Medicines Agency , Human Use , Respiratory Questionnaire , Biologics License Application , Chief Scientific Officer George , Nasal Polyposis , Forward Looking Statements , Regeneron Pharmaceuticals , Medicinal Products , Product Candidates ,